This site uses cookies to store information on your computer. Learn more x


Our bright science is helping to improve peoples’ lives and preserve the planet every day.
Novel braiding technology

Intricate medical procedures

DSM and partners Meister & Cie AG recently unveiled a novel braiding technology of DSM’s Dyneema Purity® fibers for use in the design and construction of medical devices.

The new constructions of Dyneema Purity fiber are available by means of a patented platform technology called the ‘Implantable Holding Device” developed by Meister & Cie AG. This platform technology offers medical device manufacturers greater design freedom and possibilities for device miniaturization.

DSM is extremely pleased with the benefits this new platform technology offers used in conjunction with Dyneema Purity fiber, enabling an improved generation of surgical products for the most intricate medical procedures” said Carola Hansen, Director of Product Management, Polyethylenes, DSM Biomedical.

Next generation peptide enhanced bone graft

Next generation peptide enhanced bone graft

DSM has partnered with Cerapedics to develop and manufacture the next generation peptide enhanced bone graft. The strategic partnership aligns DSM’s regenerative materials capabilities with Cerapedics’ proprietary synthetic small peptide (P-15) technology.

The partnership combines DSM’s industry leading expertise and capabilities in bioceramic materials with Cerapedics’ innovative growth factor, delivering a new product solution to improve people’s lives. “Together, from concept to commercialization, we are at the leading edge of advanced healing solutions” said David Yonce, Vice President and Global Head of Innovation at DSM Biomedical.

Cerapedics developed P-15 technology to support bone growth through cell attraction, attachment, and activation and is partnering with DSM to collaboratively develop and commercialize the next generation. “The next generation product we’re developing with DSM is showing tremendous potential, and will allow us to bring the bone forming potential of the P-15 technology into the lumbar spine,” said Jeffrey G. Marx, Ph.D., President and COO, Cerapedics.

Plastic and reconstructive surgery

Musculoskeletal Transplant Foundation partnership

In September 2017 DSM announced a new partnership with the Musculoskeletal Transplant Foundation (MTF), a U.S. non-profit service organization, to distribute biologic products for use in plastic and reconstructive surgery. The partnership will address the changing needs of hospitals and providers by offering a full suite of biologic products.

DSM’s xenograft meshes and synthetic materials used in plastic and reconstructive surgeries complement the portfolio of allograft meshes and materials offered by MTF already being distributed to Plastic and Reconstructive Surgeons.

DSM offers significant expertise in the development of regenerative biomaterials that align with MTF’s current biologics portfolio. We are excited to collaborate with DSM on the development and delivery of innovative biomaterials that serve the unmet clinical needs of patients worldwide” said Tom Shaffer, Executive Vice President of Global Sales and Marketing, MTF.

Related links